Delving into the Latest Updates on Trastuzumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-HER2/neu-MAb, Nanotrastuzumab, trastuzumab

+ [18]

Target

HER2

Action

antagonists

Mechanism

HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)

Therapeutic Areas

NeoplasmsDigestive System DisordersMouth and Tooth Diseases+ [7]

Active Indication

HER2 Positive Colorectal CancerHER2 positive salivary gland cancerHER2-positive gastric cancer+ [41]

Inactive Indication

AdenocarcinomaAdvanced breast cancerAdvanced Gastric Adenocarcinoma+ [41]

Originator Organization

Genentech, Inc.

Active Organization

F. Hoffmann-La Roche Ltd.Roche Registration GmbH

Chugai Pharmaceutical Co., Ltd.

+ [8]

Inactive Organization

Sanofi

Novartis Pharmaceuticals Corp.Western Regional Medical Center, Inc.

+ [14]

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (25 Sep 1998),

Metastatic breast cancer

RegulationPriority Review (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Sequence Code 18481L

Source: *****

Sequence Code 44772H

Source: *****

This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treating patients with HER2-positive stage IV breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or to a limited number of sites (oligometastatic). The usual approach for patients with (oligo)metastatic HER2-positive breast cancer is systemic drug treatment, which means medicines that travel through the whole body to treat both the breast and any areas where the cancer has spread. There are a number of approved HER2-targeted systemic therapy regimens available to patients. These typically include immunotherapy and/or chemotherapy. Immunotherapy drugs may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Unlike systemic therapy, locoregional therapies like surgery and radiation are focused treatments at the site of disease, delivered with the intent of sparing healthy tissues. Breast surgeries such as breast conserving therapy or total mastectomy are procedures in which the cancerous breast tissue (and healthy breast tissue in the case of total mastectomy) are surgically removed from the body. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Adding locoregional therapy, as well as metastasis-directed SBRT, to standard systemic therapy may help patients with (oligo)metastatic, HER2-positive stage IV breast cancer live longer overall or before their cancer progresses, and may help more patients achieve no evidence of disease, when compared to standard systemic therapy alone.

Start Date09 Mar 2027

Sponsor / Collaborator

SWOG

[+1]

NCT07772245

/ Not yet recruitingPhase 2IIT

Phase II Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer

The goal of this Clinical Trial is to find out how well 3 medicines (retifanlimab, trastuzumab and pertuzumab) work at treating HER2-positive breast cancer in Male and female patients, 18 or older. The main question aims to determine the pathologic response rate [residual cancer burden (RCB)- 0] in the breast and lymph nodes after 6 cycles of retifanlimab, trastuzumab and pertuzumab in patients with HER2-addicted breast cancer. Participants will will have at least 6 cycles of the study drug, assuming the participant is responding to and tolerating the treatment well. Every cycle will last about 21 days.

Start Date31 Dec 2026

Sponsor / Collaborator

The Methodist Hospital Research Institute

NCT07679269

/ Not yet recruitingPhase 2

An Open Label, Multi-center Alpelisib Roll-over Study to Assess Long-term Safety in Participants Who Have Completed a Novartis Sponsored Alpelisib (BYL719) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Alpelisib.

The purpose of this study is to provide post-trial access to alpelisib and to assess its long-term safety when administered as a single agent or in combination with other drugs. This study is intended for participants who are currently receiving alpelisib in a Novartis-sponsored clinical trial (parent study) and, in the Investigator's judgment, would benefit from continued treatment with alpelisib.

Start Date15 Dec 2026

Sponsor / Collaborator

Novartis Pharmaceuticals Australia Pty Ltd.

100 Clinical Results associated with Trastuzumab

Login to view more data

100 Translational Medicine associated with Trastuzumab

Login to view more data

100 Patents (Medical) associated with Trastuzumab

Login to view more data

12,995

Literatures (Medical) associated with Trastuzumab

01 Mar 2027·CLINICA CHIMICA ACTA

Cardiac troponin autoantibodies and cancer therapy-related cardiac dysfunction in breast cancer patients receiving anthracycline treatment: secondary analysis of the PRADA study

Article

Author: Vinje-Jakobsen, Victoria ; Wittfooth, Saara ; Gulati, Geeta ; Heck, Siri L ; Omland, Torbjørn ; Junes, Helea

BACKGROUND:

Cardiac troponins (cTn) are biomarkers for cardiac injury and used for detection and monitoring of cancer therapy-related cardiac dysfunction (CTRCD). However, cTn-specific autoantibodies (cTnAAb) can interfere with cTn measurements. The purpose of this study was to investigate the prevalence of cTnAAbs and whether cTnAAbs associate with the development of CTRCD in breast cancer patients receiving anthracyclines such as epirubicin.

METHODS:

This study included 119 patients from the PRADA trial, where study drugs metoprolol and candesartan were given concomitantly with 5-fluorouracil, epirubicin and cyclophosphamide therapy with or without trastuzumab and/or radiation. Blood samples obtained at baseline, after 1st cycle and at completion of epirubicin therapy, after possible additional treatment and at 2-year follow-up were analysed for cTnAAbs using an investigational immunoassay.

RESULTS:

We detected cTnAAbs in 6 patients (5%), out of whom 3 (50%) developed mild CTRCD, whereas 68 out of 113 (60%) cTnAAb-negative patients developed mild CTRCD (p = 1.0). High-sensitivity cTnI (Abbott) concentrations were higher in cTnAAb-positive than negative patients at baseline (median [95% CI] 2.1 [1.5, 6.1] vs. 0.8 [0.8, 1.2] ng/L, p < 0.001) and after the first cycle of anthracyclines (2.3 [1.1, 7.1] vs. 1.2 [0.8, 1.3] ng/L, p < 0.05) but not after completion of anthracycline therapy.

CONCLUSIONS:

The prevalence of cTnAAbs was low in this breast cancer cohort. The presence of cTnAAbs in circulation was associated with slightly higher initial concentrations of cTnI. No associations between the production of cTnAAbs and the development of CTRCD were observed in this study.

01 Feb 2027·BIOELECTROCHEMISTRY

Super-antifouling electrochemical biosensor based on a biomimetic gemini zwitterionic interface for sensitive detection of therapeutic antibodies

Article

Author: Qu, Jia-Huan ; Zhao, Zheng ; Han, Hai ; Li, Haidong ; Yu, Wanqing ; Chen, Zhiwei ; Jiang, Zhengjin ; Hai, MingFang ; Wang, Qiqin

Biofouling, arising from the nonspecific adsorption of proteins, cells, and other biomolecules, remains a major challenge that compromises the stability and reliability of diagnostic and therapeutic platforms. To address this issue, a super-antifouling electrochemical aptasensor was developed by integrating a biomimetic "gemini" zwitterionic monomer (BSMMP) with polydopamine (PDA). The covalent assembly of BSMMP and PDA forms a multi-site anchoring layer that enables the stable functionalization of the affinity aptamer GC20. Owing to its dense hydration shell, the PDA-BSMMP hybrid interface acts as a physical barrier against nonspecific adsorption, maintaining electron-transfer stability in undiluted human serum. Differential pulse voltammetry confirmed that this interface markedly reduced biofouling-induced signal loss, limiting attenuation to less than 15%, nearly fourfold lower than that of the unmodified surface. The platform achieved a low limit of detection of 0.97 ng/mL, a broad linear range from 1 ng/mL to 100 μg/mL, and high selectivity for trastuzumab in a label-free format without secondary antibodies or additional signal amplification. Finally, this platform successfully quantified trastuzumab in serum from breast cancer patients, with results consistent with commercial ELISA kits. Overall, this super-antifouling aptasensor offers great potential for therapeutic drug monitoring, advancing zwitterionic interface-based biosensing strategies for point-of-care diagnostics.

01 Jan 2027·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Development and application of antibody framework region-targeted cross-linking mass spectrometry for epitope screening within patient-derived immune complexes

Article

Author: Aibara, Nozomi ; Ohyama, Kaname ; Nakamura, Minoru ; Matsugi, Yuya ; Kutsuna, Yuki Jimbayashi ; Hamasaki, Maya ; Kawakami, Atsushi ; Yamazawa, Ryuji ; Nakashima, Mikiro

Identification of antibody-binding epitopes on antigens is essential for understanding the pathogenic roles of immune complexes (ICs) in autoimmune diseases and for the development of diagnostics and therapeutics. However, methods for direct epitope characterization of IC-antigens formed in vivo remain limited. Here, we investigated antibody framework region (FR)-targeted cross-linking mass spectrometry (XL-MS) as an approach to identify epitopes in patient-derived ICs. Four IC models with known epitopes (tumor necrosis factor alpha-adalimumab, tumor necrosis factor alpha-infliximab, human epidermal growth factor receptor 2-pertuzumab, and human epidermal growth factor receptor 2-trastuzumab) were analyzed using three cross-linkers of different lengths: bis(sulfosuccinimidyl) suberate (BS3), bis(sulfosuccinimidyl) glutarate (BS2G), and 1,1'-carbonyldiimidazole (CDI). BS3 preferentially generated antigen-FR cross-links, whereas CDI predominantly produced antigen-complementarity-determining region cross-links. Several cross-linked peptides contained antigen sequences overlapping previously reported epitopes, supporting the validity of this approach for epitope mapping. As a proof-of-concept clinical application, serum samples from patients with primary biliary cholangitis were analyzed using a targeted database containing four disease-associated autoantigens (PDC-E2, BCOADC-E2, OGDC-E2, and E3BP). Two candidate epitope peptides were identified. One corresponded to a known immunodominant epitope, whereas the other represented a novel candidate site supported by computational epitope prediction analysis. These findings demonstrate that FR-targeted XL-MS provides a strategy for identifying epitopes within patient-derived IC-antigens through the use of conserved antibody FRs. This approach may contribute to understanding antigen recognition mechanisms in autoimmune diseases and support the discovery of disease-relevant therapeutic targets.

1,150

News (Medical) associated with Trastuzumab

02 Nov 2026

·www.biospace.com

Iksuda to Present Clinical Data for IKS014 in HER2+ Solid Tumours at SABCS

Excellent therapeutic pro manageable and differentiated safety pro promising anti-tumour activity in patients with a range of advanced HER-2-expressing solid tumours Positive activity in a subset of HER2+ breast cancer patients previously treated with Enhertu (T-DXd) NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of preliminary data from its Phase 1 study for its HER2-directed ADC, IKS014, which is being assessed in patients with advanced or metastatic HER2+, HER2-low and HER2-mutated solid tumours, at the San Antonio Breast Cancer Symposium (SABCS), December 8-11, 2026, San Antonio, Texas. Additionally, the presentation includes a pooled analysis from dose escalation- and dose-expansion phases of the trial for a sub-set of HER2+ breast cancer patients who have previously received trastuzumab-deruxtecan (Enhertu/ ‘T-DXd’). This is an important patient population given the clinical challenges of ADC sequencing, and with T-DXd now approved as a front-line treatment in these patients. As of April 2026, 105 patients with a variety of tumours were enrolled across Part I dose escalation and Part II dose expansion cohorts. Overall, 71 patients were enrolled in Part 1 dose escalation (DE) /enrichment cohorts and treated at doses from 40 – 120 mg/m 2 once every three weeks. A maximum tolerated dose (MTD) was not identified but a dose of 105 mg/m 2 was selected for further evaluation in expansion cohorts based on its promising efficacy across tumour types and a good, differentiated safety profile. 34 patients have been enrolled into Part II to date across 5 expansion cohorts (ECs), one of which (IIA) includes patients with HER2+ BC previously treated with T-DXd. In the 105 patients, IKS014 has been shown to be well tolerated with a differentiated and manageable safety profile. Only 16 patients (15.2%) experienced Grade 3 treatment-related adverse events (TRAEs), of which seven patients (6.7%) experienced hypokalaemia as the most common event. Compared with other HER2-directed ADCs, there was a notable absence in the frequency of high-grade, pneumonitis/ILD, neutropenia, anaemia, fatigue, AST elevation and GI toxicities. The most common TRAEs were low-grade (G1 or G2) hypokalaemia (36%), dry eye (34%), keratitis (34%) and dry mouth (28%). No Grade 5 events or treatment-related serious adverse events were noted. Pooled efficacy analysis consisted of 10 response-evaluable patients with advanced or metastatic HER2+ breast cancer previously treated with T-DXd, including four patients treated at ≥90 mg/m 2 in DE cohorts and six patients treated in the EC. Patients were heavily pre-treated, with a median number of regimens of 6 and a range of 2-12. The objective response rate was 50% (n=5/10), which consisted of confirmed and unconfirmed partial responses. Of particular note, PRs were observed in patients who had a best response of PD to prior T-DXd, and sustained responses were also observed, including in one patient with a response of over 18 months. Alongside the good safety profile, these efficacy results are highly encouraging. As an evolving dataset, the final SABCS presentation will contain updated data. The IIA EC will recruit 25 patients in total. Expansion Cohort IIA will continue to recruit patients with HER2+ BC previously treated with T-DXd, whilst patients with advanced or metastatic HER2-low BC, HER2+ gastric/ GEJ and oesophageal cancers, and HER2-mutated lung cancer will continue to be recruited to the additional expansion cohorts. Dr. Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, commented: “The data from our Phase 1 study of IKS014 is extremely exciting, with promising antitumor activity seen in patients with advanced HER2+ solid tumours across multiple histologies, alongside a differentiated and manageable safety profile. We are strongly encouraged by the efficacy in patients who have previously received T-DXd, a patient population with high unmet need, and we look forward to continuing with dose expansion and the enrolment of these patients.” Dr. James O’Leary, Chief Medical Officer at Iksuda Therapeutics, added: “ These data demonstrate the potential of IKS014 to address the high unmet need across various HER2-positive cancers, including for patients who have not responded to previous lines of treatment.” The Phase 1 study ( NCT05872295 ) is an open-label, multicentre trial of IKS014 in patients with HER2-expressing advanced solid tumours refractory to or progressing after standard therapies. Part I (Dose Escalation) will establish a recommended Expansion Dose and Part 2 (Dose Expansion) will further evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of IKS014 in five cohorts, including one for patients with HER2+ breast cancer who have previously been treated with T-DXd. IKS014 has been evaluated by a separate sponsor in trials conducted exclusively in China, including an ongoing Phase 3 trial in breast cancer. Presentation details Abstract number: 602 Presentation Number: PS3-1 Title: A Phase 1 study of IKS014 (caxmotabart entudotin) in patients with HER2+ solid tumours, and preliminary activity in breast cancer patients previously treated with trastuzumab deruxtecan Presentation Date/Time: Wednesday, December 9, 2026, 7:00 AM - 8:30 AM CST Location: 301 ABC About IKS014 IKS014 is a potential best-in-class antibody drug conjugate, benefiting from tumour selective activation and release of the cytotoxic agent monomethyl auristatin F (MMAF). In preclinical trials, it displayed impressive activity in high- and low-HER2 expressing tumours with a favourable Therapeutic Index compared with other HER2-directed drugs. Iksuda gained exclusive world-wide rights (excluding Greater China and South Korea) to IKS014 from LigaChem Biosciences ( ) . About Iksuda Therapeutics: Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading ADCs targeting difficult-to-treat haematological and solid tumours. Iksuda’s pipeline of ADCs is centred on a portfolio of prodrug ADCs which utilise tumour-selective release and activation of payloads, incorporating proprietary and in-licensed (from LigaChem Biosciences) prodrug and linker technologies in combination with stable conjugation chemistries including its proprietary PermaLink ® platform. The early pipeline incorporates Iksuda’s proprietary, first-in-class protein alkylating payload class, ProAlk™. The Company’s design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer. Contacts For further information please contact: Iksuda Therapeutics Dave Simpson, Chief Executive Officer Tel: +44 (0) 191 6031680 info@iksuda.com FTI Consulting (Financial Media and IR) Simon Conway / Natalie Garland-Collins / Amy Byrne Tel: +44 (0) 020 3727 1000 Iksuda@fticonsulting.com

Phase 1Clinical ResultADCDrug ApprovalPhase 3

26 Oct 2026

·firstwordpharma.com

'Modest' benefit scuppers BioNTech's breast cancer ambitions for trastuzumab pamirtecan

BioNTech and DualityBiologics said Monday that a Phase III study of trastuzumab pamirtecan (BNT323/DB-1303) in chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer who have progressed on endocrine therapy met its primary endpoint of progression-free survival (PFS). However, the overall results from the DYNASTY-Breast02 trial suggest that the HER2-targeting antibody-drug conjugate (ADC) will not be progressing in this setting.While the companies noted that trastuzumab pamirtecan demonstrated a statistically significant improvement in PFS over investigator's choice of chemotherapy, they described the benefit as "modest." They also said that there was a higher rate of interstitial lung disease (ILD) than seen in prior studies of trastuzumab pamirtecan — although most cases were grade 1 and 2 — as well as "severe and fatal events…in a small proportion of patients."The global trial enrolled patients with HR+/HER2-low metastatic breast cancer whose disease has progressed on at least two lines of prior hormone therapy or within six months of first line hormone therapy plus CDK 4/6 inhibitor in the metastatic setting. A total of 541 participants with HER2-low expression were randomised to receive either trastuzumab pamirtecan or investigator's choice of single-agent chemotherapy, comprising capecitabine, paclitaxel or nab-paclitaxel. Along with the primary endpoint of PFS, DYNASTY-Breast02 is measuring overall survival (OS) as a secondary goal. BioNTech and DualityBio said Monday that data for OS were not yet mature at this interim analysis.Given the outcome, the companies concluded that trastuzumab pamirtecan's "potential benefit to patients would be limited in the context of the HR+/HER2-low metastatic breast cancer treatment landscape." The partners plan to review the data before determining next steps.AstraZeneca and Daiichi Sankyo's HER2-targeting ADC Enhertu (trastuzumab deruxtecan) is authorised in both the US and EU for the treatment of adults with unresectable or metastatic HR+, HER2-low or HER2-ultralow breast cancer that has progressed on one or more endocrine therapies in the metastatic setting. The approvals are based on the Phase III DESTINY-Breast06 study, in which patients with HER2-low tumours had a 36% lower chance of their cancer growing or spreading compared with chemotherapy.Outside of DYNASTY-Breast02, BioNTech and DualityBio are investigating trastuzumab pamirtecan in the Phase III Fern-EC-01 study for previously-treated patients with HER2-expressing advanced recurrent endometrial cancer.

Phase 3Clinical ResultDrug ApprovalADC

26 Oct 2026

·www.biopharmadive.com

BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study

An antibody-drug conjugate from BioNTech and DualityBio met its main goal in a Phase 3 study in breast cancer, but may only have a limited impact in people with the condition, the companies said Monday.The treatment, known as trastuzumab pamirtecan, successfully delayed tumor progression in a trial of people whose breast tumors express low, but still detectable levels of the HER2 protein. The improvement on that measure was modest, though, and treatment was also associated with higher rates of interstitial lung disease a potentially deadly kind of lung inflammation than the companies had seen in earlier testing.The partners also revealed that severe and fatal events were observed in a small proportion of patients. They revealed, too, that the trial hadnt been run long enough to detect a clear survival benefit. The combined findings suggest that the potential benefit to patients would be limited given the current treatment landscape for HER2-low metastatic breast cancer. The companies will discuss the data and determine next steps, they said.Trastuzumab pamirtecan is involved in two other ongoing trials. One is a late-stage study in HER2-positive endometrial cancer. The other is an early-stage study in advanced, metastatic solid tumors.BioNTech obtained trastuzumab pamirtecan through a 2023 licensing deal with DualityBio that marked BioNTechs first foray into antibody-drug conjugates, or ADCs. Potentially worth more than $1.6 billion overall, that pact was part of a broader effort by BioNTech to pursue oncology research and rely on more than its core messenger RNA technology.That strategy has produced mixed results so far. Prior to Mondays announcement, the company had reported two otherclinical setbacks.ADCs have become a mainstay of cancer care and, in some tumor types, have been able to supplant traditional chemotherapy. One of those examples is in breast cancer, where AstraZeneca and Daiichi Sankyos Enhertu is deeply entrenched across multiple treatment lines. Enhertu gained the first-ever approval of a therapeutic for HER2-low disease in 2022 and followed that up with a clearance in tumors with ultralow HER2 expression three years later.Like Enhertu, trastuzumab pamirtecan is an ADC aimed at the HER2 protein. '

License out/inPhase 3ADCClinical ResultDrug Approval

100 Deals associated with Trastuzumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03257	Trastuzumab	L01FD01	DB00072

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
HER2 Positive Colorectal Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
HER2 positive salivary gland cancer	Japan	Chugai Pharmaceutical Co., Ltd.	25 Nov 2021
HER2-positive gastric cancer	Japan	Chugai Pharmaceutical Co., Ltd.	10 Mar 2011
Stomach Cancer	United States	Genentech, Inc.	20 Oct 2010
Breast Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	04 Apr 2001
Early Stage Breast Carcinoma	European Union	Roche Registration GmbH	28 Aug 2000
Early Stage Breast Carcinoma	Iceland	Roche Registration GmbH	28 Aug 2000
Early Stage Breast Carcinoma	Liechtenstein	Roche Registration GmbH	28 Aug 2000
Early Stage Breast Carcinoma	Norway	Roche Registration GmbH	28 Aug 2000
HER2 Positive Breast Cancer	European Union	Roche Registration GmbH	28 Aug 2000
HER2 Positive Breast Cancer	Iceland	Roche Registration GmbH	28 Aug 2000
HER2 Positive Breast Cancer	Liechtenstein	Roche Registration GmbH	28 Aug 2000
HER2 Positive Breast Cancer	Norway	Roche Registration GmbH	28 Aug 2000
HER2 positive Gastroesophageal Junction Adenocarcinoma	European Union	Roche Registration GmbH	28 Aug 2000
HER2 positive Gastroesophageal Junction Adenocarcinoma	Iceland	Roche Registration GmbH	28 Aug 2000
HER2 positive Gastroesophageal Junction Adenocarcinoma	Liechtenstein	Roche Registration GmbH	28 Aug 2000
HER2 positive Gastroesophageal Junction Adenocarcinoma	Norway	Roche Registration GmbH	28 Aug 2000
Hormone receptor positive breast cancer	European Union	Roche Registration GmbH	28 Aug 2000
Hormone receptor positive breast cancer	Iceland	Roche Registration GmbH	28 Aug 2000
Hormone receptor positive breast cancer	Liechtenstein	Roche Registration GmbH	28 Aug 2000

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 3	United Kingdom	-	07 Mar 2023
Colorectal Cancer	Phase 3	United Kingdom	-	07 Mar 2023
Gallbladder Neoplasms	Phase 3	United Kingdom	-	07 Mar 2023
Hematologic Neoplasms	Phase 3	United Kingdom	-	07 Mar 2023
Lung Cancer	Phase 3	United Kingdom	-	07 Mar 2023
Ovarian Cancer	Phase 3	United Kingdom	-	07 Mar 2023
Pancreatic Cancer	Phase 3	United Kingdom	-	07 Mar 2023
Prostatic Cancer	Phase 3	United Kingdom	-	07 Mar 2023
Salivary Gland Neoplasms	Phase 3	United Kingdom	-	07 Mar 2023
Skin Neoplasms	Phase 3	United Kingdom	-	07 Mar 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2026	Not Applicable	Carcinosarcoma \| Uterine Serous Carcinoma HER2-positive \| HER2-expressing	742	trastuzumab plus carboplatin-paclitaxel	-	Positive	23 Oct 2026
ESMO2026	Not Applicable		742	trastuzumab deruxtecan	etfktafjaq(iermfnosyv) = xamzahxpkt qzlnybvsnt (xflqptxfwp, 84 - 98) View more	Positive	23 Oct 2026
NCT06832904 (NEOTORCH-BREAST05, ESMO2026)	Phase 2	HER2 Positive Breast Cancer Neoadjuvant HER2-positive	38	Neoadjuvant chemotherapy + Pyrotinib + trastuzumab	iepyzaoouc(odgviapgil) = diarrhea (29, 76.3%) xfrmobdnwn (pmqchodulx ) View more	Positive	23 Oct 2026
ChiCTR2500095130 (ESMO2026)	Phase 2	HER2 Positive Breast Cancer Neoadjuvant HER2-positive	15	EriCbHP (eribulin, carboplatin, trastuzumab, and pertuzumab)	uejvrzecet(udyjborors) = dpnbextyxz mgazanamyr (gtoyqdetzt, 38.6 - 90.9) View more	Positive	23 Oct 2026
ESMO2026	Not Applicable	HER2 Positive Breast Cancer Neoadjuvant HER2-positive	74	Subcutaneous dual HER2 blockade	omkggfroav(jnbqynmiez) = enttditeeo sauhbfsiac (zjwxwnlbez )	Positive	23 Oct 2026
ESMO2026	Not Applicable	HER2 Positive Breast Cancer Neoadjuvant HER2-positive	74	Intravenous dual HER2 blockade	omkggfroav(jnbqynmiez) = xffnafbjmz sauhbfsiac (zjwxwnlbez )	Positive	23 Oct 2026
ESMO2026	Not Applicable	HER2 Positive Breast Cancer Neoadjuvant HER2-positive	78	Trastuzumab and Pertuzumab	exmfeifnnl(atvcztjviy) = nsbivgulok khtlutawvf (rbpbuxtddm )	Positive	23 Oct 2026
NCT04588545 (INSPIRE-LM, ESMO2026)	Phase 2	Metastatic Malignant Neoplasm to the Leptomeninges HER2+	30	Radiation therapy + IT trastuzumab + pertuzumab	plcrphwtgf(frntdstwlq) = djmrfrjofw jznzxqhluk (lemvyxghtg ) View more	Positive	23 Oct 2026
ESMO2026	Not Applicable	HER2 Positive Breast Cancer Neoadjuvant HER2-positive	160	Trastuzumab plus pertuzumab	vkdzqreqri(phggxvunpd) = mnthivdcyj hbnfykrnez (vbyrvghebg ) View more	Positive	23 Oct 2026
ESMO2026	Not Applicable	HER2 Positive Breast Cancer Neoadjuvant HER2-positive	160	Trastuzumab alone	dmffqfxfwp(dzfghxbjqw) = oiulsqotms tqqqxuqmmg (nbsiutpafq ) View more	Positive	23 Oct 2026
ESMO2026	Not Applicable	Gastrooesophageal junction cancer HER2 \| MSI-H/dMMR \| PD-L1	345	Trastuzumab	xdsbbzpdub(oscrjqjbnq) = mtogtynbtx plilnscxzz (zccrjueqky ) View more	Positive	23 Oct 2026
ESMO2026	Not Applicable	Gastrooesophageal junction cancer HER2 \| MSI-H/dMMR \| PD-L1	345	Immune checkpoint inhibitors (ICIs)	xdsbbzpdub(oscrjqjbnq) = qwgexqbbka plilnscxzz (zccrjueqky ) View more	Positive	23 Oct 2026
NCT01973660 (PAMELA, ESMO2026)	Phase 2	HER2 Positive Breast Cancer Neoadjuvant HER2-positive	72	trastuzumab/lapatinib	hcudaektie(kzrqqgobyl) = xqgbqbdytm tjomlqnnai (sumufvjuzs ) View more	Positive	23 Oct 2026
NCT05885776 (PHEDRA, ESMO2026)	Phase 2	HER2 Positive Breast Cancer Neoadjuvant HER2 positive \| HR positive	48	Pyrotinib + Trastuzumab + AI	wevkixxtlh(whgwqxzpmx) = fagujtduuh tnyurmlzkx (wlfcfgybxa ) View more	Positive	23 Oct 2026

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Trastuzumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation